TenQ · fact sheet · filings current to · price as of
AbbVie (ABBV)
A mixed picture - strengths and real weaknesses - 24 of 36 checks passed.
Latest close : $256.46, -1.4% on the day; -3.6% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $256.46 |
| Market cap | $453.2B |
| 52-week range | $195.99 - $265.97 |
| P/E | 72.1x |
| P/E, own 11-year median | 18.8x |
| P/S | 7.0x |
| Free cash flow yield | 4.0% |
| Dividend yield | 2.6% |
| Revenue (TTM) | $64.4B |
| Net income (TTM) | $6.3B |
| Free cash flow (TTM) | $18.2B |
| Gross margin | 71.5% |
| Operating margin | 26.2% |
| Return on equity | - |
| Revenue growth (1y) | +10.4% |
| Revenue CAGR (3y) | +1.8% |
| Debt / equity | - |
| Cash & short-term investments | $6.6B |
| Shares outstanding | 1,767.1m (cover page of the latest filing, 2026-07-27) |
The score: 24 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is ABBV stock cheap or expensive right now?
Value · 1 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is AbbVie still growing?
Growth · 3 of 6 checks passed. Growing, but with caveats - revenue +10.4% over the last year. chapter →
Does AbbVie make real money?
Quality · 5 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can AbbVie survive a bad year?
Health · 3 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does AbbVie hand back to shareholders?
Shareholder returns · 6 of 6 checks passed. Owners are paid reliably and affordably, and the share count is not eroding their stake. chapter →
Which way is ABBV trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling ABBV?
Open-market buys: $0.00 · sells: $19M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · Abbott Laboratories (ABT) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.